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Abstract 
Low dose antihypertensive drugs in combination are prescribed frequently in clinical practice.  
Combination treatment is superior to monotherapy with higher doses of each drug in terms of 
blood pressure reduction and side effects.  However, it is unclear whether combination 
treatment provides additional prognostic benefit beyond the blood pressure lowering effects.  
We assessed the usefulness of the combined treatment of a renin-angiotensin system inhibitor 
(RASI) and a calcium channel blocker (CCB) for all cardiovascular events in the Japanese 
Coronary Artery Disease (JCAD) Study population.  In the JCAD Study, which is an 
observational and non-randomized trial, 13,812 patients with angiographically shown 
narrowing > 50% in ≥ 1 of 3 major coronary arteries were followed up for a mean of 2.7 years.  
The primary endpoint of the study was all cardiovascular events.  In the present study, 
baseline covariates possibly influencing the event rate were adjusted between the different 
treatment groups.  There was no statistically significant difference in the event rate between 
the RASI monotherapy and combined treatment groups, although Kaplan-Meier analysis 
showed a 23% (p = 0.0003) relative risk reduction with an RASI monotherapy compared with 
the control group.  In conclusion, there may be no additional benefit beyond blood pressure 
lowering effects in combination of an RASI and a CCB in patients with angiographically 
documented CAD. 
 
 
Key words  Calcium channel blocker · Combination therapy · Coronary artery disease · 
Renin-angiotensin system inhibitor 
3 
Introduction 
It is well known that the use of antihypertensive agents in combination provides a synergistic 
or at least an additive blood pressure reduction, which is greater than higher doses of each 
drug used as monotherapy.
1-4
  Combination low dose drug treatment also reduces side 
effects.
1, 2
  The combination of a renin-angiotensin system inhibitor (RASI) and a calcium 
channel blocker (CCB) is frequently used in clinical practice.
5
  Since both an RASI and a 
CCB possibly provide cardiovascular protection by improving vascular function,
6-8
 it is 
postulated that combination therapy might provide prognostic benefit beyond the blood 
pressure lowering effects.  Thus, we compared prognostic effects of an RASI and a CCB 
alone or in combination beyond the blood pressure lowering effects after adjustment for 
baseline covariates including the blood pressure in the Japanese Coronary Artery Disease 
(JCAD) Study population.
9
 
 
Materials and methods 
The protocol and major outcomes of the JCAD study were previously published.
9
  Briefly, 
we consecutively enrolled patients with angiographically demonstrable narrowing > 50% in ≥ 
1 of 3 major coronary arteries.  Initially, 15,628 patients were registered and 13,812 patients 
were followed up for a mean of 2.7 years (follow-up rate 88.4%).  Clinical events to be 
registered in the database were defined as all-cause deaths, including cardiac, cerebral, 
4 
vascular and other deaths, and cerebral, cardiac and vascular events.  Cerebral events 
included cerebral hemorrhage, cerebral infarction and transient ischemic attack.  Cardiac 
events consisted of fatal and nonfatal myocardial infarction, unstable angina, congestive heart 
failure, coronary bypass graft surgery, resuscitated cardiac arrest, and cardiopulmonary arrest 
on arrival.  Angiographic restenosis incidentally found during routine follow-up coronary 
angiography without clinical symptoms was excluded from events registration.  Aortic 
dissection and rupture of an aortic aneurysm were classified as vascular events.  The primary 
endpoint of the present study was all cardiovascular events.  The data of this study was 
derived from a post-hoc analysis of an observational, non-randomized trial. 
Informed consent was obtained from each patient and the study protocol conformed to 
the ethical guidelines of the 1975 Declaration of Helsinki as reflected in a priori approval by 
the institution’s human research committee. 
 
Statistical analysis 
Numerical data are presented as the mean value ± SD.  Unpaired Student’s t-test was applied 
for the comparison of parametric values, while comparisons of variables between the 2 groups 
were made by the Wilcoxon test for non-parametric unpaired values.  Proportional data were 
analyzed by the chi-square test.  Propensity score matching analysis was used to match 
baseline characteristics between the 2 groups.
10
  Kaplan-Meier hazard ratios were used to 
5 
examine the incidence over time, and the log-rank test was used to assess group differences.  
Two-sided p < .05 was regarded as statistically significant. 
 
Results 
As shown in Table 1, baseline covariates potentially influencing the cardiovascular event were 
adjusted between the 2 groups by the propensity score matching method.  However, systolic 
blood pressure was slightly but significantly higher (1.3 mmHg in mean) in the control group 
than the RASI monotherapy group (Table 1-A), and was slightly but significantly lower (1.9 
mmHg in mean) in the control group than the combination treatment group (Table 1-C).  It 
was also significantly lower (3.1 mmHg in mean) in the RASI monotherapy group than the 
combination treatment group (Table 1-D).  Kaplan-Meier analysis showed a 23% relative 
risk reduction of all cardiovascular events with the RASI monotherapy compared with the 
control group.  Log-rank test showed a statistically significant difference (p = 0.0003) in the 
event rate between the 2 groups (Fig. 1A).  Meanwhile, there was no statistically significant 
difference in the incidence of all cardiovascular events between the control and the CCB 
monotherapy groups (Fig. 1B).  Furthermore, no statistically significant difference in the 
incidence of all cardiovascular events was observed between the control and combination 
treatment groups (Fig. 1C).  There was also no statistically significant difference in the 
incidence of all cardiovascular events between the RASI monotherapy and combination 
6 
treatment groups (Fig. 1D). 
Cumulative hazard analysis of endpoints of subcategories revealed similar results of the 
composite endpoint.  Cerebral events in the RASI monotherapy group was significantly 
lower than the combination treatment group (Table 2). 
Table 3 shows follow-up blood pressure levels in each group.  There were slight but 
significant differences in the systolic blood pressure levels between the combination treatment 
group and the untreated control or RASI monotherapy group over the 3 years follow-up 
periods. 
 
Discussion 
In the current study, baseline covariates, including coronary risk factors such as hypertension, 
hyperlipidemia, impaired glucose tolerance and tobacco use were adjusted between the 
control and treatment groups by the propensity score matching method.
10
  As a result, 
additional effects beyond blood pressure lowering of an RASI and a CCB alone, or in 
combination were successfully evaluated.  The findings of this study suggest that the 
usefulness of combination of an RASI and a CCB beyond blood pressure lowing may not 
exist.  This implies that the beneficial effects of the combination treatment with an RASI and 
a CCB compared with each monotherapy are largely due to the blood pressure lowering 
effects.  In previous studies indicating the usefulness of combination therapy, blood pressure 
7 
levels were significantly lower in the combination treatment.
1-4
  Thus, there may be no 
additional beneficial effects of combination of an RASI and a CCB.  This may be explained, 
at least in part, by the difference between the clinical situation and experimental study where 
more than ten-fold dose of a CCB was used to unravel the vascular protective effect of the 
drug.
7
 Although the RASI monotherapy was effective in terms of the prevention of 
cardiovascular events, the reason why the significantly favorable effect of an RASI 
disappeared by addition of a CCB is unclear.  The slight but significantly higher blood 
pressure in the combination treatment group as compared with the untreated control and RASI 
monotherapy groups may have counterbalanced the effectiveness of the combination 
treatment.  Thus, there is a possibility that “reversal of cause and effect” may have brought 
about in the present study. 
In the blood pressure-lowering arm of the Anglo-Scandinavian Cardiac Outcomes Trial 
(ASCOT)
11
, 5137 hypertensive patients with diabetes mellitus were randomized to amlodipine 
with addition of perindopril or atenolol with addition of thiazide, and were followed-up for 5 
years.  The amlodipine-based treatment reduced the incidence of total cardiovascular events 
and procedures by 14% compared with the atenolol-based treatment.  The mean systolic and 
diastolic pressures were 3.0 mmHg and 1.9 mmHg lower among those on the 
amlodipine-based treatment.  Blood levels of glucose, creatinine and triglyceride throughout 
the study were significantly higher among patients on the atenolol-based treatment.  
8 
Above-mentioned differences between the 2 treatment arms may explain the superiority of the 
combination of a CCB with an RASI to that of a beta-blocker with a diuretic. 
In the Avoiding Cardiovascular Events through Combination Therapy in Patients Living 
with Systolic Hypertension (ACCOMPLISH) trial,
12
 it has been demonstrated that the 
benazepril-amlodipine combination treatment is superior to the 
benazepril-hydrochlorothiazide combination in reducing cardiovascular events in high risk 
patients with hypertension (relative risk reduction; 19.6%, p < 0.001).  Mean blood pressure 
after dose adjustment was significantly lower in the benezepril-amlodipine group compared 
with the benazepril-hydrochlorothiazide group.  The mean difference in blood pressure 
between the two groups was 0.9 mmHg systolic and 1.1 mmHg diastolic.  A small but 
significant difference in blood pressure may explain the superiority of the 
benezepril-amlodipine group.  Alternatively, the combination of a CCB with an RASI may 
provide unique beneficial effects beyond the blood pressure lowering effects as compared to 
the combination of an RASI with a diuretic. 
There are several limitations to the present study.  First, it is likely that there is a bias 
that relates to individuals in this cohort treated with an RASI and/or a CCB, being more 
severely ill than others.  However, despite this residual bias, the hazard ratios tended to be 
lower in each of the drug treated group compared to the untreated control group (Fig 1-A, B, 
C).  Above-mentioned bias inherent to the observational study may have obviated the 
9 
difference between the RASI monotherapy and combination treatment groups, because 
complete matching regarding risk factors, exercise,
13
 drug usage
14
 and severity of diseases 
between the 2 groups is difficult due to the limitation of the propensity score matching (Fig 
1-D).  Second, in this study cohort, the prevalence of patients with hypertension was 
approximately 50% to 70%, therefore it may be limited to extrapolate these results to patients 
with hypertension.  Finally, the randomization of patients to each treatment arm was not 
conducted, because the JCAD study was an observational, non-randomized trial.  In this 
meaning, to clarify the usefulness of combination treatment beyond the blood pressure 
lowering effects, a prospective, randomized trial consisting of an RASI or a CCB 
monotherapy and the combination treatment groups are needed, although the exact matching 
of blood pressure levels between the monotherapy and the combination treatment may be 
difficult.  In conclusion, our findings suggest that there may be no additional prognostic 
benefit beyond blood pressure lowering effects in combination of an RASI and a CCB in 
patients with CAD. 
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Figure Legend 
Figure 1. 
Cumulative hazard of all cardiovascular events in patients not receiving an RASI and a CCB 
and those receiving an RASI but no CCB (A), a CCB but no RASI (B), and both an RASI and 
a CCB (C).  Cumulative hazard of all cardiovascular events in patients receiving an RASI 
but no CCB and those receiving both an RASI and a CCB (D). 
CCB = calcium channel blocker; CI = confidence interval; HR = hazard ratio; RASI = 
rennin-angiotensin system inhibitor. 
Table 1-A 
Baseline characteristics of patients after propensity score matching 
Variables No RASI, no CCB RASI, but no CCB p value 
Patients receiving an RASI, but no CCB   
No. of patients 2,447 2,447  
Age (yrs) 65.5 ± 10.3 64.5 ± 10.0 0.9205 
Men 79.1% 78.5% 0.5998 
Hypertension 48.6% 49.2% 0.6473 
Hyperlipidemia 56.6% 55.9% 0.6040 
Impaired glucose tolerance 38.9% 39.6% 0.5983 
Body mass index ≥ 25 (kg/m2) 30.9% 31.2% 0.8288 
Tobacco use 43.1% 43.0% 0.9310 
Alcohol intake 39.6% 39.7% 0.9534 
Family history of coronary artery disease 15.6% 16.0% 0.6952 
Heart failure 12.4% 12.0% 0.6620 
Left main coronary narrowing 4.4% 4.0% 0.4765 
Number of coronary arteries narrowed 1.8 ± 0.8 1.8 ± 0.8 0.9581 
Systolic blood pressure (mmHg) 130.5 ± 20.1 129.2 ± 20.2 0.0039 
Diastolic blood pressure (mmHg) 74.2 ± 12.1 74.2 ± 12.2 0.5275 
Total cholesterol (mg/dl) 195.9 ± 39.0 196.8 ± 38.1 0.3549 
Fasting blood sugar (mg/dl) 121.5 ± 48.9 122.4 ± 48.4 0.1442 
Angiotensin-converting enzyme inhibitors 0% 71.6% 0.0000 
Angiotensin receptor blockers 0% 30.3% 0.0000 
 
Values are the mean ± SD or percentage of each characteristic. 
CCB = calcium channel blocker; RASI = renin-angiotensin system inhibitor; Hypertension was 
defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; 
Hyperlipidemia was defined as total cholesterol ≥ 220 mg/dl or low density lipoprotein cholesterol ≥ 
140 mg/dl or triglyceride ≥ 150 mg/dl. 
Table 1-B 
Baseline characteristics of patients after propensity score matching 
Variables No RASI, no CCB CCB, but no RASI p value 
Patients receiving a CCB, but no RASI   
No. of patients 2,659 2,659  
Age (yrs) 65.3 ± 9.9 65.3 ± 9.7 0.8263 
Men 77.5% 77.5% 0.9476 
Hypertension 50.2% 50.0% 0.8909 
Hyperlipidemia 57.4% 57.6% 0.9116 
Impaired glucose tolerance 38.2% 39.5% 0.3680 
Body mass index ≥ 25 (kg/m2) 31.1% 32.1% 0.4259 
Tobacco use 37.8% 37.3% 0.6918 
Alcohol intake 38.0% 38.6% 0.6517 
Family history of coronary artery disease 15.9% 15.4% 0.6238 
Heart failure 7.0% 7.0% 0.9572 
Left main coronary narrowing 5.3% 5.2% 0.9510 
Number of coronary arteries narrowed 1.8 ± 0.8 1.8 ± 0.8 0.7075 
Systolic blood pressure (mmHg) 131.5 ± 20.1 131.9 ± 18.2 0.3305 
Diastolic blood pressure (mmHg) 74.2 ± 12.0 74.3 ± 11.8 0.9703 
Total cholesterol (mg/dl) 197.7 ± 39.1 197.9 ± 38.4 0.7003 
Fasting blood sugar (mg/dl) 120.9 ± 47.4 120.0 ± 44.9 0.6105 
 
Values are the mean ± SD or percentage of each characteristic. 
CCB = calcium channel blocker; RASI = renin-angiotensin system inhibitor; Hypertension was 
defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; 
Hyperlipidemia was defined as total cholesterol ≥ 220 mg/dl or low density lipoprotein cholesterol ≥ 
140 mg/dl or triglyceride ≥ 150 mg/dl. 
Table 1-C 
Baseline characteristics of patients after propensity score matching 
Variables No RASI, no CCB RASI and CCB p value 
Patients receiving an RASI and a CCB   
No. of patients 1,903 1,903  
Age (yrs) 65.5 ± 9.7 65.6 ± 9.5 0.6973 
Men 75.8% 76.0% 0.8795 
Hypertension 69.8% 69.8% 1.0000 
Hyperlipidemia 58.5% 58.8% 0.8434 
Impaired glucose tolerance 41.6% 42.3% 0.6694 
Body mass index ≥ 25 (kg/m2) 34.7% 34.4% 0.8647 
Tobacco use 38.3% 38.5% 0.8940 
Alcohol intake 39.0% 38.5% 0.7393 
Family history of coronary artery disease 15.7% 16.2% 0.6582 
Heart failure 9.9% 9.7% 0.8701 
Left main coronary narrowing 4.2% 4.6% 0.4763 
Number of coronary arteries narrowed 1.8 ± 0.8 1.8 ± 0.8 0.2933 
Systolic blood pressure (mmHg) 134.9 ± 20.9 136.8 ± 21.0 0.0375 
Diastolic blood pressure (mmHg) 75.6 ± 12.3 75.7 ± 12.6 0.5903 
Total cholesterol (mg/dl) 197.3 ± 38.6 197.2 ± 36.8 0.8362 
Fasting blood sugar (mg/dl) 123.9 ± 49.8 121.2 ± 46.2 0.4278 
Angiotensin-converting enzyme inhibitors 0% 71.4% 0.0000 
Angiotensin receptor blockers 0% 31.1% 0.0000 
 
Values are the mean ± SD or percentage of each characteristic. 
CCB = calcium channel blocker; RASI = renin-angiotensin system inhibitor; Hypertension was 
defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; 
Hyperlipidemia was defined as total cholesterol ≥ 220 mg/dl or low density lipoprotein cholesterol ≥ 
140 mg/dl or triglyceride ≥ 150 mg/dl. 
Table 1-D 
Baseline characteristics of patients after propensity score matching 
Variables RASI, but no CCB RASI and CCB p value 
Patients receiving an RASI and a CCB   
No. of patients 1,901 1,901  
Age (yrs) 65.2 ± 9.6 65.3 ± 9.5 0.9449 
Men 76.9% 77.1% 0.8472 
Hypertension 69.4% 69.9% 0.7778 
Hyperlipidemia 56.8% 57.9% 0.4911 
Impaired glucose tolerance 43.0% 42.6% 0.7932 
Body mass index ≥ 25 (kg/m2) 34.1% 34.0% 0.9454 
Tobacco use 42.1% 41.8% 0.8695 
Alcohol intake 40.9% 41.5% 0.7170 
Family history of coronary artery disease 16.8% 17.1% 0.7623 
Heart failure 12.5% 13.2% 0.5281 
Left main coronary narrowing 3.5% 3.7% 0.7287 
Number of coronary arteries narrowed 1.8 ± 0.8 1.8 ± 0.8 0.9997 
Systolic blood pressure (mmHg) 133.6 ± 21.1 136.7 ± 21.4 0.0000 
Diastolic blood pressure (mmHg) 75.8 ± 12.9 75.7 ± 12.7 0.7263 
Total cholesterol (mg/dl) 195.2 ± 37.6 195.6 ± 36.5 0.9230 
Fasting blood sugar (mg/dl) 124.0 ± 50.0 121.5 ± 46.8 0.2644 
Angiotensin-converting enzyme inhibitors 70.2% 72.1% 0.1977 
Angiotensin receptor blockers 31.8% 30.5% 0.3812 
 
Values are the mean ± SD or percentage of each characteristic. 
CCB = calcium channel blocker; RASI = renin-angiotensin system inhibitor; Hypertension was 
defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg; 
Hyperlipidemia was defined as total cholesterol ≥ 220 mg/dl or low density lipoprotein cholesterol ≥ 
140 mg/dl or triglyceride ≥ 150 mg/dl.
Table 2 
Cumulative hazard of cardiac and cerebral events 
Groups 
No. of  
events 
No. of 
patients 
HR 95% CI p value 
Cardiac events      
    RASI (–)  CCB (–) 336 2,447 0.7487 0.6367-0.8804 0.0005 
    RASI (+)  CCB (–) 260 2,447    
      
    RASI (–)  CCB (–) 337 2,659 0.8927 0.7651-1.0415 0.1485 
    RASI (–)  CCB (+) 312 2,659    
      
    RASI (–)  CCB (–) 265 1,903 0.9054 0.7615-1.0766 0.2607 
    RASI (+)  CCB (+) 250 1,903    
      
    RASI (+)  CCB (–) 216 1,901 1.0790 0.8975-1.2973 0.4185 
    RASI (+)  CCB (+) 240 1,901    
      
Cerebral events      
    RASI (–)  CCB (–) 47 2,447 0.6779 0.4321-1.0634 0.0886 
    RASI (+)  CCB (–) 33 2,447    
      
    RASI (–)  CCB (–) 49 2,659 0.9433 0.6344-1.4025 0.7731 
    RASI (–)  CCB (+) 49 2,659    
      
    RASI (–)  CCB (–) 41 1,903 1.0364 0.6783-1.5834 0.8687 
    RASI (+)  CCB (+) 45 1,903    
      
    RASI (+)  CCB (–) 23 1,901 1.9742 1.1864-3.3020 0.0077 
    RASI (+)  CCB (+) 44 1,901    
      
 
CCB = calcium channel blocker; CI = confidence interval; HR = hazard ratio; RASI = 
renin-angiotensin system inhibitor. 
Table 3 
Follow-up blood pressure levels 
 Baseline 1 Year 2 Years 3 Years 
Systolic blood pressure     
RASI (–)  CCB (–) 
131±20 
(n=2,447) 
131±18 
(n=1,609) 
131±17 
(n=1,355) 
131±17 
(n=1,269) 
RASI (+)  CCB (–) 
129±20* 
(n=2,447) 
131±18 
(n=2,051) 
131±17 
(n=1,747) 
131±17 
(n=1,650) 
     
RASI (–)  CCB (–) 
132±20 
(n=2,659) 
131±18 
(n=1,754) 
131±17 
(n=1,462) 
131±17 
(n=1,383) 
RASI (–)  CCB (+) 
132±18 
(n=2,659) 
131±17 
(n=2,249) 
131±17 
(n=1,900) 
131±16 
(n=1,829) 
     
RASI (–)  CCB (–) 
135±21 
(n=1,903) 
133±18 
(n=1,224) 
131±18 
(n=1,015) 
131±17 
(n=961) 
RASI (+)  CCB (+) 
137±21* 
(n=1,903) 
135±18* 
(n=1,621) 
133±18* 
(n=1,395) 
133±17* 
(n=1,341) 
     
RASI (+)  CCB (–) 
134±21 
(n=1,901) 
132±18 
(n=1,572) 
132±17 
(n=1,332) 
132±17 
(n=1,244) 
RASI (+)  CCB (+) 
137±21† 
(n=1,901) 
136±18† 
(n=1,611) 
134±18† 
(n=1,388) 
134±17† 
(n=1,335) 
     
Diastolic blood pressure     
    RASI (–)  CCB (–) 
74±12 
(n=2,447) 
75±11 
(n=1,609) 
74±10 
(n=1,355) 
74±11 
(n=1,269) 
    RASI (+)  CCB (–) 
74±12 
(n=2,447) 
74±11 
(n=2,051) 
74±11 
(n=1,747) 
74±10 
(n=1,650) 
     
    RASI (–)  CCB (–) 
74±12 
(n=2,659) 
74±11 
(n=1,754) 
74±10 
(n=1,462) 
74±11 
(n=1,383) 
    RASI (–)  CCB (+) 
74±12 
(n=2,659) 
74±10 
(n=2,249) 
74±10 
(n=1,900) 
74±10 
(n=1,829) 
     
    RASI (–)  CCB (–) 
76±12 
(n=1,903) 
75±11 
(n=1,224) 
74±10 
(n=1,015) 
75±11 
(n=961) 
    RASI (+)  CCB (+) 
76±13 
(n=1,903) 
75±11 
(n=1,621) 
75±11 
(n=1,395) 
74±11 
(n=1,341) 
     
    RASI (+)  CCB (–) 
76±13 
(n=1,901) 
75±11 
(n=1,572) 
75±11 
(n=1,332) 
75±10 
(n=1,244) 
    RASI (+)  CCB (+) 
76±13 
(n=1,901 
75±11 
(n=1,611) 
74±11 
(n=1,388) 
74±11 
(n=1,335) 
 
Values are the mean ± SD. 
CCB = calcium channel blocker; RASI = renin-angiotensin system inhibitor. 
* p < 0.05 vs. RASI (–)  CCB (–); †p<0.05 vs. RASI (+) CCB (–). 
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Figure 1-B
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Figure 1-C
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Figure 1-D
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